THYROCARE
vs
B
BSE Sensex 30
THYROCARE
Over the past 12 months, THYROCARE has significantly outperformed BSE Sensex 30, delivering a return of +71% compared to the BSE Sensex 30's +11% growth.
Stocks Performance
THYROCARE vs BSE Sensex 30
Performance Gap
THYROCARE vs BSE Sensex 30
Performance By Year
THYROCARE vs BSE Sensex 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Thyrocare Technologies Ltd
Glance View
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
